Objectives. The aim of this study was to investigate a possible association between tardive dyskinesia (TD) and CYP1A2 (*1F, -163C>А, rs762551) polymorphism in Russian psychiatric inpatients. Methods. TD was assessed cross-sectionally using the Abnormal Involuntary Movement Scale (AIMS). Orofacial and limb-truncal dyskinesia were assessed with AIMS 1-4 and 5-7, respectively. Standard protocols were applied for genotyping. Analysis of covariance (ANCOVA) was used to compare the mean AIMS scores for each of the genotypic classes. Results. A total of 319 Caucasian patients from West Siberia with schizophrenia and 117 healthy volunteers were investigated. No significant differences between the patients and the controls in genotype frequencie...
Background: Tardive dyskinesia (TD) is a potentially irreversible consequence of long term treatment...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Polymorphic variants of CYP1A2 and CYP2D6 genes of the cytochrome P450 system were studied in patien...
Objectives. The aim of this study was to investigate a possible association between tardive dyskines...
Understanding the pharmacogenetic basis of developing iatrogenic disorders such as Tardive Dyskinesi...
Tardive dyskinesia (TD) is an iatrogenic disorder observed in ~20-30% of schizophrenia patients on l...
Typical antipsychotic treatment had been postulated to be a risk factor for the susceptibility to ta...
Identifying biomarkers which can be used as a diagnostic tool is a major objective of pharmacogeneti...
Tardive dyskinesia (TD) is a potentially irreversible antipsychoticinduced movement disorder with a ...
Background: Tardive dyskinesia (TD) is an extrapyramidal side effect of the long-term use of antipsy...
Background: Tardive dyskinesia is a disorder characterized by involuntary muscle movements that occu...
Background Cytochrome P450 1A2 gene (CYP1A2) polymorphisms have been suggested to be associated w...
OBJECTIVES: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD)....
Background: Tardive dyskinesia (TD) is a potentially irreversible consequence of long term treatment...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Polymorphic variants of CYP1A2 and CYP2D6 genes of the cytochrome P450 system were studied in patien...
Objectives. The aim of this study was to investigate a possible association between tardive dyskines...
Understanding the pharmacogenetic basis of developing iatrogenic disorders such as Tardive Dyskinesi...
Tardive dyskinesia (TD) is an iatrogenic disorder observed in ~20-30% of schizophrenia patients on l...
Typical antipsychotic treatment had been postulated to be a risk factor for the susceptibility to ta...
Identifying biomarkers which can be used as a diagnostic tool is a major objective of pharmacogeneti...
Tardive dyskinesia (TD) is a potentially irreversible antipsychoticinduced movement disorder with a ...
Background: Tardive dyskinesia (TD) is an extrapyramidal side effect of the long-term use of antipsy...
Background: Tardive dyskinesia is a disorder characterized by involuntary muscle movements that occu...
Background Cytochrome P450 1A2 gene (CYP1A2) polymorphisms have been suggested to be associated w...
OBJECTIVES: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD)....
Background: Tardive dyskinesia (TD) is a potentially irreversible consequence of long term treatment...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Polymorphic variants of CYP1A2 and CYP2D6 genes of the cytochrome P450 system were studied in patien...